Drug Type Mesenchymal stem cell therapy |
Synonyms aMBMC(Medstar Health Research Institute) |
Target- |
Mechanism Stem cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-ischemic Cardiomyopathy | Phase 2 | US | 03 May 2019 | |
Myocardial Ischemia | Preclinical | US | 03 May 2019 |
Phase 2 | 4 | (Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)) | (wlzyrpyjua) = zdtefozylk vmtjenjwem (wwshocssqt, jimigxlwpf - wwgpxnpoyv) View more | - | 02 Feb 2022 | ||
Placebo (Placebo) | (wlzyrpyjua) = ecwzfhdmgq vmtjenjwem (wwshocssqt, pfazsubpcw - ejirtlecmj) View more |